DEADLINE NEXT WEEK: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, alleging violations of the Securities Exchange Act of 1934 related to misleading information about its clinical trials and safety protocols [1][4][5]. Group 1: Lawsuit Details - The lawsuit, titled Ho v. Rocket Pharmaceuticals, Inc., is pending in the District of New Jersey and seeks to represent purchasers of Rocket Pharmaceuticals' securities [1]. - A subsequent case, Yankov v. Rocket Pharmaceuticals, Inc., has also been filed [1]. - The allegations include that Rocket Pharmaceuticals provided misleading information regarding its Phase 2 trial of RP-A501 for Danon disease while concealing serious risks, including participant deaths [4]. Group 2: Clinical Trial Issues - The lawsuit claims that Rocket Pharmaceuticals failed to disclose a critical amendment to the trial protocol that introduced a new immunomodulatory agent, which was linked to serious adverse events [4]. - On May 27, 2025, the U.S. FDA placed a clinical hold on the RP-A501 study after a patient died, which was not disclosed to investors at the time of the protocol amendment [5]. Group 3: Legal Process - Investors who suffered losses can seek to be appointed as lead plaintiff in the class action lawsuit, with motions due by August 11, 2025 [2][6]. - The lead plaintiff will represent the interests of all class members and can choose their legal representation [6]. Group 4: Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class actions for four out of the last five years [7].